Trials Sponsors Conditions Drugs Pricing

Conditions

Leukemia, Myelocytic, Acute

Keywords

Dendritic cellsLymphocytesAML

Outcome Measures

Primary Outcomes (1)

Participant Toxicity Levels
Participant toxicity of infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL) in relapsed patients after allo-stem cell transplants.
From stem cell transplant baseline to 30 plus days post transplant.

Study Arms (1)

Apheresis + Transplant

EXPERIMENTAL

Skin biopsy \& either a leukodepletion apheresis or an additional marrow aspiration prior to marrow or stem cell transplantation.

Procedure: ApheresisBiological: Stem Cell Transplant

Interventions

ApheresisProcedure

Apheresis for T-Cell collection

Apheresis + Transplant

Stem Cell TransplantBiological

Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).

Also known as: SCT, Stem Cell Transplantation

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

AML (any type except M3) or CIVIL in blast crisis with greater than or equal to 20% bone marrow blasts at the time of related donor marrow or stem cell transplantation or at relapse post transplant.
Willing to undergo a skin biopsy and either a leukodepletion apheresis or an additional marrow aspiration.

Sponsors & Collaborators

National Cancer Institute (NCI)
NIHcollaborator
M.D. Anderson Cancer Center
Otherlead

Study Sites (1)

M.D. Anderson Cancer Center

Houston, Texas, 77030-4009, United States

MeSH Terms

Conditions

Leukemia, Myeloid, Acute

Interventions

Blood Component RemovalStem Cell Transplantation

Condition Hierarchy (Ancestors)

Leukemia, MyeloidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic Diseases

Intervention Hierarchy (Ancestors)

TherapeuticsCell TransplantationCell- and Tissue-Based Therapy

Study Officials

Elizabeth J. Shpall, MD
UT MD Anderson Cancer Center
PRINCIPAL INVESTIGATOR

Enrollment

2 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NA
Masking: NONE
Purpose: TREATMENT
Intervention Model: SINGLE GROUP
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

October 24, 2002

First Posted

October 25, 2002

Study Start

February 2001

Date type not reported

This date has not been verified as actual or estimated.

Study Stopped

Anti-Leukemic Dendritic Cell Activated Donor Lymphocytes

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Apheresis + Transplant

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Study Arms (1)

Apheresis + Transplant

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Links

MeSH Terms

Conditions

Interventions

Condition Hierarchy (Ancestors)

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

You may not qualify if:

Source record

Locations